In this article
Summary
How ten peptides and molecules target aging-related pathways, what the studies actually show, and where proposed benefits remain unproven.
Ten research products, not ten proven longevity treatments
Anti-aging research is not one field or one mechanism. Scientists investigate senescent cells, mitochondrial function, nutrient sensing, cellular recycling, and neuronal resilience. FOXO4-DRI, Epithalon, SS-31, AICAR, Pinealon, spermidine, Urolithin A, rapamycin, CMS-121, and P-21 approach different pieces of that biology. Several are peptides; others are small molecules or a naturally occurring polyamine.
This 2026 overview explains the requested selection, not a sales-based popularity ranking. A plausible mechanism is a research rationale, not proof of longer human life. Cell experiments, mouse studies, and human randomized trials answer different questions. The studies discussed here do not establish that these ten supplier products extend human lifespan or work safely together.
FOXO4-DRI and Epithalon: senescent cells versus telomere biology
FOXO4-DRI is a senolytic research peptide designed to disrupt the interaction between FOXO4 and p53. In Baar and colleagues' 2017 study, that disruption promoted apoptosis in senescent cells. Mouse experiments reported improvements in measures including fitness and kidney function. The potential benefit being investigated is reducing the burden of dysfunctional cells, not simply making every cell younger. These were laboratory and animal findings, not a demonstration of safe rejuvenation in people.
Epithalon, also spelled Epitalon, is a tetrapeptide investigated for telomere maintenance. A 2025 cell-line study reported telomerase-related telomere extension in normal cells and alternative lengthening activity in cancer cells. The paper has an associated correction. This provides a mechanistic reason to study cellular aging, but longer telomeres are not automatically better clinical outcomes. Cancer-cell responses underscore why long-term safety cannot be assumed. Synthetic Epithalon should not be conflated with the distinct pineal preparation Epithalamin.
SS-31 and AICAR: mitochondrial function and energy sensing
SS-31, or elamipretide, is a mitochondria-targeted tetrapeptide associated with cardiolipin and mitochondrial protein interactions. Researchers investigate whether improving mitochondrial organization and energy handling can preserve tissue function. That is a different approach from removing damaged mitochondria. Human regulatory context matters: FDA granted accelerated approval to the specific medicine Forzinity in 2025 for Barth syndrome in patients weighing at least 30 kilograms. This is not approval for general anti-aging, and it does not validate a research supplier's SS-31 product as an interchangeable medicine.
AICAR is a small molecule used to study AMPK, a cellular energy-sensing pathway. In a 2008 mouse study, AICAR treatment increased metabolic gene expression and treadmill endurance in sedentary animals. The possible research benefit is improved metabolic adaptation under particular experimental conditions. It is not evidence that people can replace exercise with AICAR, prevent frailty, or live longer. Endurance in a controlled mouse experiment is a narrower outcome than healthy aging in humans.
Pinealon and P-21: neuronal resilience, with important identity limits
Pinealon is the tripeptide Glu-Asp-Arg. Cell experiments have reported lower reactive oxygen species accumulation and less necrotic cell death under oxidative stress, with changes in ERK signaling and cell-cycle behavior. These results motivate investigation of neuronal stress resistance. They do not establish prevention of dementia, improved memory in healthy adults, or longer lifespan. A protective response in cultured cells cannot tell us the net effect of long-term exposure in a person.
P-21 is the name used on the linked supplier listing. Scientific papers discuss P021, a CNTF-derived neurotrophic peptide mimetic investigated for neurogenesis, BDNF-related signaling, and cognition in preclinical models. These names alone do not prove identical sequence, formulation, or activity. A 2024 study found benefits in a cellular CDKL5-deficiency model but limited behavioral benefit and no correction of neuroanatomical defects in the mouse model. Verify chemical identity before transferring a P021 result to a product labeled P-21. Potential neurotrophic activity is not established human cognitive enhancement.
Spermidine and Urolithin A: cellular recycling and human trial signals
Spermidine is a naturally occurring polyamine, not a peptide. It is studied for roles in protein regulation and autophagy, the process cells use to recycle components. This creates a plausible research connection to cellular maintenance and brain aging. However, the 12-month SmartAge randomized trial in 100 older adults with subjective cognitive decline did not find a significant benefit on its primary memory outcome. Exploratory findings are not a substitute for that result, and dietary-supplement studies do not establish equivalence with a laboratory product.
Urolithin A is a gut-microbiome-derived metabolite studied for mitophagy, the selective recycling of mitochondria. In a randomized trial involving 66 older adults, researchers reported improvements in some muscle-endurance measures and biomarkers. The primary six-minute-walk and maximal ATP-production outcomes did not significantly improve compared with placebo. Maintaining muscle function is an important potential benefit to investigate, but the mixed endpoints do not demonstrate reversal of aging, longer life, or the same effects from every Urolithin A formulation.
Rapamycin: nutrient sensing with a real risk-benefit question
Rapamycin, also called sirolimus, inhibits mTOR signaling, a pathway involved in growth and nutrient responses. Harrison and colleagues reported increased median and maximal lifespan in genetically heterogeneous mice when treatment began late in life. This is a significant animal finding and a reason mTOR remains important in geroscience. It is not a human lifespan result.
The research question is whether carefully controlled modulation of this pathway can preserve function without unacceptable harms. Rapamycin's immunosuppressive pharmacology and potential adverse effects make it inappropriate to frame as a harmless wellness supplement. Human studies, indications, formulations, and safety monitoring must be considered separately. A commercial research listing does not establish suitability for self-treatment, and combining it with other compounds is not justified merely because their mechanisms sound complementary.
CMS-121: lipid metabolism and experimental neuroprotection
CMS-121, usually written CMS121 in papers, is a small-molecule research candidate rather than a peptide. A 2020 study identified fatty acid synthase as a molecular target and reported reduced lipid peroxidation, inflammation, and cognitive loss in a transgenic Alzheimer's mouse model. Researchers are examining whether controlling damaging lipid chemistry can protect vulnerable neurons.
The potential benefit is preservation of brain function under specific disease-related conditions. That remains different from showing that CMS-121 prevents Alzheimer's disease or slows normal aging in humans. A positive result in one experimental model is a starting point for replication, pharmacology, and clinical testing, not a reason to equate a research capsule with an established treatment.
Sources: [15]
How to read the evidence and the product links
Ask which organism was studied, whether the main endpoint improved, how long the study lasted, and whether the tested material matches the product being discussed. Biomarker changes, better endurance, and lifespan extension are different outcomes. A citation-count graph shows source coverage, not a ranking of effectiveness. None of this review supplies a dosing plan or a recommended combination.
The research-material cards link all ten requested compounds to Base Peptides. These are commercial laboratory listings, not clinical recommendations or independently verified assurances of purity. Disclosure: Peptide Basics' founder also founded Base Peptides. Product availability does not establish benefit, regulatory approval, or safety for human use. Read the original studies and distinguish promising biological questions from conclusions that have actually been tested.
Source coverage by section
Number of distinct cited sources attached to each section. This shows citation coverage only. It does not measure evidence quality, study strength, or effectiveness.
View as table
References
Based on indexed abstracts retrieved through Europe PMC. Full texts were not independently reviewed. Automated checks can miss errors; consult the original publications before drawing conclusions.
- Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging.. Published 2017-03-01. Accessed 2026-10-24.Source
- Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.. Published 2025-09-04. Accessed 2026-10-24.Source
- Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.. Published 2025-11-15. Accessed 2026-10-24.Source
- Mitochondrial protein interaction landscape of SS-31.. Published 2020-06-17. Accessed 2026-10-24.Source
- AMPK and PPARdelta agonists are exercise mimetics.. Published 2008-07-31. Accessed 2026-10-24.Source
- Effects of Spermidine Supplementation on Cognition and Biomarkers in Older Adults With Subjective Cognitive Decline: A Randomized Clinical Trial.. Published 2022-05-02. Accessed 2026-10-24.Source
- Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial.. Published 2022-01-04. Accessed 2026-10-24.Source
- Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.. Published 2009-07-08. Accessed 2026-10-24.Source
- Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes.. Published 2011-10-06. Accessed 2026-10-24.Source
- Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound.. Published 2022-10-02. Accessed 2026-10-24.Source
- Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder.. Published 2024-11-26. Accessed 2026-10-24.Source
- Spermidine in Alzheimer's Disease: Evidence from Animal Models and Human Studies.. Published 2026-06-20. Accessed 2026-10-24.Source
- Bench to bedside: is rapamycin headed for the docTOR?. Published 2026-05-13. Accessed 2026-10-24.Source
- CMS121, a fatty acid synthase inhibitor, protects against excess lipid peroxidation and inflammation and alleviates cognitive loss in a transgenic mouse model of Alzheimer's disease.. Published 2020-07-21. Accessed 2026-10-24.Source
- FDA Grants Accelerated Approval to First Treatment for Barth Syndrome. Published 2025-09-19. Accessed 2026-10-24.Source
Research materials
Compounds mentioned in this article with verified supplier destination pages for laboratory research. A listing is not independent verification of product quality or clinical suitability.
Research use only. Listed products are sold for laboratory research, are not approved for human or veterinary use, and are not a clinical recommendation. Nothing here suggests a dose, protocol, or treatment.
Business relationship. Peptide Basics' founder also founded Base Peptides, and we may have commercial relationships with listed suppliers. Product details are on the supplier's site and are not independently verified by us.
Research & Educational Use Only
This article summarizes published research for educational purposes. It is not medical advice and does not recommend any compound, dose, or treatment. See our editorial standards.
Developed & Edited by Brian Gossett
Created with AI-assisted research and drafting. See our editorial standards for the publication and review process.
Founder & Biotechnology Research Industry Entrepreneur
20+ years of entrepreneurial experience • Peptide & biotechnology industry experience
View Staff Profile →Disclosure: Brian is the founder of Base Peptides, a large research peptide supplier. Full disclosure.
Found an error? Review our Corrections Policy or contact us.